{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:48:17Z","timestamp":1784299697168,"version":"3.55.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,9]]},"DOI":"10.7759\/cureus.101180","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:37:27Z","timestamp":1767983847000},"source":"Crossref","is-referenced-by-count":3,"title":["Gastrointestinal Stromal Tumors: Histopathological Spectrum, Molecular Subtypes, and Implications for Targeted Therapy"],"prefix":"10.7759","author":[{"given":"Hussein","family":"Qasim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abu Shugaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad  N","family":"Awawdeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Dawaymeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karis","family":"Khattab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musallam","family":"Al-oweiwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo Luigi Giuseppe","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v5.i6.102","article-title":"A gist of gastrointestinal stromal tumors: a review","volume":"5","author":"Rammohan A","year":"2013","unstructured":"Rammohan A, Sathyanesan J, Rajendran K, et al.. A gist of gastrointestinal stromal tumors: a review. World J Gastrointest Oncol. 2013, 5:102-12. 10.4251\/wjgo.v5.i6.102","journal-title":"World J Gastrointest Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2078-6891.2012.031","article-title":"Gastrointestinal stromal tumor","volume":"3","author":"Zhao X","year":"2012","unstructured":"Zhao X, Yue C. Gastrointestinal stromal tumor. J Gastrointest Oncol. 2012, 3:189-208. 10.3978\/j.issn.2078-6891.2012.031","journal-title":"J Gastrointest Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2025.111569","article-title":"Gastrointestinal stromal tumors with atypical features and presentations: a case series","volume":"133","author":"Aregawi AB","year":"2025","unstructured":"Aregawi AB, Fenta BD, Worku MA, Geremew TT. Gastrointestinal stromal tumors with atypical features and presentations: a case series. Int J Surg Case Rep. 2025, 133:10.1016\/j.ijscr.2025.111569","journal-title":"Int J Surg Case Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2014.08.351","article-title":"Clinical presentation, management and outcomes of gastrointestinal stromal tumors","volume":"12","author":"Al-Thani H","year":"2014","unstructured":"Al-Thani H, El-Menyar A, Rasul KI, et al.. Clinical presentation, management and outcomes of gastrointestinal stromal tumors. Int J Surg. 2014, 12:1127-33. 10.1016\/j.ijsu.2014.08.351","journal-title":"Int J Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14740\/jmc3631","article-title":"Gastrointestinal stromal tumor: an uncommon but serious cause of gastrointestinal bleeding","volume":"12","author":"Alawawdeh F","year":"2021","unstructured":"Alawawdeh F, Al-Tkrit A, Aneeb M, Mekaiel A, Mehta A. Gastrointestinal stromal tumor: an uncommon but serious cause of gastrointestinal bleeding. J Med Cases. 2021, 12:74-8. 10.14740\/jmc3631","journal-title":"J Med Cases"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-025-01185-y","article-title":"Artificial intelligence-assisted prostate cancer diagnosis for reduced use of immunohistochemistry","volume":"5","author":"Blilie A","year":"2025","unstructured":"Blilie A, Mulliqi N, Ji X, et al.. Artificial intelligence-assisted prostate cancer diagnosis for reduced use of immunohistochemistry. Commun Med (Lond). 2025, 5:425. 10.1038\/s43856-025-01185-y","journal-title":"Commun Med (Lond)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21945","article-title":"Histopathology of gastrointestinal stromal tumor","volume":"104","author":"Miettinen M","year":"2011","unstructured":"Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011, 104:865-73. 10.1002\/jso.21945","journal-title":"J Surg Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091707","article-title":"Utility of clinical next generation sequencing tests in KIT\/PDGFRA\/SDH wild-type gastrointestinal stromal tumors","volume":"16","author":"Denu RA","year":"2024","unstructured":"Denu RA, Joseph CP, Urquiola ES, et al.. Utility of clinical next generation sequencing tests in KIT\/PDGFRA\/SDH wild-type gastrointestinal stromal tumors. Cancers (Basel). 2024, 16:10.3390\/cancers16091707","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.5869","article-title":"Tyrosine kinase inhibitors significantly improved survival outcomes in patients with metastatic gastrointestinal stromal tumour: a multi-institutional cohort study","volume":"27","author":"Tan AD","year":"2020","unstructured":"Tan AD, Willemsma K, MacNeill A, et al.. Tyrosine kinase inhibitors significantly improved survival outcomes in patients with metastatic gastrointestinal stromal tumour: a multi-institutional cohort study. Curr Oncol. 2020, 27:276-82. 10.3747\/co.27.5869","journal-title":"Curr Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17070923","article-title":"Tyrosine kinase inhibitors for gastrointestinal stromal tumor after imatinib resistance","volume":"17","author":"Xiao XH","year":"2025","unstructured":"Xiao XH, Zhang QS, Hu JY, Zhang YX, Song H. Tyrosine kinase inhibitors for gastrointestinal stromal tumor after imatinib resistance. Pharmaceutics. 2025, 17:10.3390\/pharmaceutics17070923","journal-title":"Pharmaceutics"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164081","article-title":"Evaluation of systemic treatment options for gastrointestinal stromal tumours","volume":"15","author":"Gol\u010di\u0107 M","year":"2023","unstructured":"Gol\u010di\u0107 M, Jones RL, Huang P, Napolitano A. Evaluation of systemic treatment options for gastrointestinal stromal tumours. Cancers (Basel). 2023, 15:10.3390\/cancers15164081","journal-title":"Cancers (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-024-01272-7","article-title":"Current drug resistance mechanisms and treatment options in gastrointestinal stromal tumors: summary and update","volume":"25","author":"He C","year":"2024","unstructured":"He C, Wang Z, Yu J, Mao S, Xiang X. Current drug resistance mechanisms and treatment options in gastrointestinal stromal tumors: summary and update. Curr Treat Options Oncol. 2024, 25:1390-405. 10.1007\/s11864-024-01272-7","journal-title":"Curr Treat Options Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203513","article-title":"Insights into metabolic reprogramming in tumor evolution and therapy","volume":"16","author":"Chiu CF","year":"2024","unstructured":"Chiu CF, Guerrero JJ, Regalado RR, et al.. Insights into metabolic reprogramming in tumor evolution and therapy. Cancers (Basel). 2024, 16:10.3390\/cancers16203513","journal-title":"Cancers (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2006.09.001","article-title":"Gastrointestinal stromal tumors: pathology and prognosis at different sites","volume":"23","author":"Miettinen M","year":"2006","unstructured":"Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006, 23:70-83. 10.1053\/j.semdp.2006.09.001","journal-title":"Semin Diagn Pathol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2018.08.20","article-title":"Gastrointestinal stromal tumors: a comprehensive review","volume":"10","author":"Parab TM","year":"2019","unstructured":"Parab TM, DeRogatis MJ, Boaz AM, et al.. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol. 2019, 10:144-54. 10.21037\/jgo.2018.08.20","journal-title":"J Gastrointest Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0b013e318050aa66","article-title":"Distinguishing gastrointestinal stromal tumors from their mimics: an update","volume":"14","author":"Abraham SC","year":"2007","unstructured":"Abraham SC. Distinguishing gastrointestinal stromal tumors from their mimics: an update. Adv Anat Pathol. 2007, 14:178-88. 10.1097\/PAP.0b013e318050aa66","journal-title":"Adv Anat Pathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v13.i30.109445","article-title":"Small bowel ulcers and bleeding: an overlooked yet critical clinical challenge","volume":"13","author":"Barbosa OA","year":"2025","unstructured":"Barbosa OA. Small bowel ulcers and bleeding: an overlooked yet critical clinical challenge. World J Clin Cases. 2025, 13:10.12998\/wjcc.v13.i30.109445","journal-title":"World J Clin Cases"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13020479","article-title":"Mesenchymal tumors of the liver: an update review","volume":"13","author":"Choi JH","year":"2025","unstructured":"Choi JH, Thung SN. Mesenchymal tumors of the liver: an update review. Biomedicines. 2025, 13:10.3390\/biomedicines13020479","journal-title":"Biomedicines"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-02853-y","article-title":"Gastrointestinal stromal tumors (GISTs) with remarkable cystic change: a specific subtype of GISTs with relatively indolent behaviors and favorable prognoses","volume":"145","author":"Xue A","year":"2019","unstructured":"Xue A, Yuan W, Gao X, et al.. Gastrointestinal stromal tumors (GISTs) with remarkable cystic change: a specific subtype of GISTs with relatively indolent behaviors and favorable prognoses. J Cancer Res Clin Oncol. 2019, 145:1559-68. 10.1007\/s00432-019-02853-y","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2014.02.004","article-title":"Gastrointestinal stromal tumors (GIST) related emergencies","volume":"12","author":"Sorour MA","year":"2014","unstructured":"Sorour MA, Kassem MI, Ghazal Ael-H, El-Riwini MT, Abu Nasr A. Gastrointestinal stromal tumors (GIST) related emergencies. Int J Surg. 2014, 12:269-80. 10.1016\/j.ijsu.2014.02.004","journal-title":"Int J Surg"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07297-9","article-title":"Defining tumor rupture in gastrointestinal stromal tumor","volume":"26","author":"Nishida T","year":"2019","unstructured":"Nishida T, H\u00f8lmebakk T, Raut CP, Rutkowski P. Defining tumor rupture in gastrointestinal stromal tumor. Ann Surg Oncol. 2019, 26:1669-75. 10.1245\/s10434-019-07297-9","journal-title":"Ann Surg Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1487467","article-title":"Pathologic diagnosis and molecular features of gastrointestinal stromal tumors: a mini-review","volume":"14","author":"Kim Y","year":"2024","unstructured":"Kim Y, Lee SH. Pathologic diagnosis and molecular features of gastrointestinal stromal tumors: a mini-review. Front Oncol. 2024, 14:10.3389\/fonc.2024.1487467","journal-title":"Front Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13143997","article-title":"Understanding gastric GIST: from pathophysiology to personalized treatment","volume":"13","author":"Moga DF","year":"2024","unstructured":"Moga DF, Vl\u0103doiu G, Fr\u0103\u021bil\u0103 AM, Dan AA, Popa D, Oprea V. Understanding gastric GIST: from pathophysiology to personalized treatment. J Clin Med. 2024, 13:10.3390\/jcm13143997","journal-title":"J Clin Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1148\/rg.336135507","article-title":"Beyond the GIST: mesenchymal tumors of the stomach","volume":"33","author":"Kang HC","year":"2013","unstructured":"Kang HC, Menias CO, Gaballah AH, Shroff S, Taggart MW, Garg N, Elsayes KM. Beyond the GIST: mesenchymal tumors of the stomach. Radiographics. 2013, 33:1673-90. 10.1148\/rg.336135507","journal-title":"Radiographics"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S444532","article-title":"Epithelioid subtype gastrointestinal stromal tumors of stomach in an endoscopic biopsy: a potential diagnostic pitfall","volume":"16","author":"Xu W","year":"2023","unstructured":"Xu W, Tang H, Chen Y, Wang J, Chen Z, Xu Y, Guo D. Epithelioid subtype gastrointestinal stromal tumors of stomach in an endoscopic biopsy: a potential diagnostic pitfall. Onco Targets Ther. 2023, 16:1043-9. 10.2147\/OTT.S444532","journal-title":"Onco Targets Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040705","article-title":"The identity of PDGFRA D842V-mutant gastrointestinal stromal tumors (GIST)","volume":"13","author":"Rizzo A","year":"2021","unstructured":"Rizzo A, Pantaleo MA, Astolfi A, Indio V, Nannini M. The identity of PDGFRA D842V-mutant gastrointestinal stromal tumors (GIST). Cancers (Basel). 2021, 13:10.3390\/cancers13040705","journal-title":"Cancers (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2022.04.005","article-title":"Gastrointestinal stromal tumors and the general surgeon","volume":"102","author":"Caturegli I","year":"2022","unstructured":"Caturegli I, Raut CP. Gastrointestinal stromal tumors and the general surgeon. Surg Clin North Am. 2022, 102:625-36. 10.1016\/j.suc.2022.04.005","journal-title":"Surg Clin North Am"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000463","article-title":"Gastrointestinal stromal tumors: variants and some pitfalls that they create","volume":"31","author":"Ibrahim A","year":"2024","unstructured":"Ibrahim A, Montgomery EA. Gastrointestinal stromal tumors: variants and some pitfalls that they create. Adv Anat Pathol. 2024, 31:354-63. 10.1097\/PAP.0000000000000463","journal-title":"Adv Anat Pathol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-010-0886-8","article-title":"Peripheral nerve sheath tumors of the gastrointestinal tract: a multicenter study of 58 patients including NF1-associated gastric schwannoma and unusual morphologic variants","volume":"456","author":"Agaimy A","year":"2010","unstructured":"Agaimy A, M\u00e4rkl B, Kitz J, et al.. Peripheral nerve sheath tumors of the gastrointestinal tract: a multicenter study of 58 patients including NF1-associated gastric schwannoma and unusual morphologic variants. Virchows Arch. 2010, 456:411-22. 10.1007\/s00428-010-0886-8","journal-title":"Virchows Arch"},{"key":"ref30","article-title":"Myxoid epithelioid gastrointestinal stromal tumor harboring an unreported PDGFRA mutation: report of a case and review of the literature","volume":"8","author":"Tajima S","year":"2015","unstructured":"Tajima S, Ohata A, Koda K, Maruyama Y. Myxoid epithelioid gastrointestinal stromal tumor harboring an unreported PDGFRA mutation: report of a case and review of the literature. Int J Clin Exp Pathol. 2015, 8:5821-9.","journal-title":"Int J Clin Exp Pathol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3087","article-title":"Advances in sarcoma genomics and new therapeutic targets","volume":"11","author":"Taylor BS","year":"2011","unstructured":"Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S, Ladanyi M. Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer. 2011, 11:541-57. 10.1038\/nrc3087","journal-title":"Nat Rev Cancer"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050679","article-title":"Clinical diagnosis of gastrointestinal stromal tumor (GIST): from the molecular genetic point of view","volume":"11","author":"Wu CE","year":"2019","unstructured":"Wu CE, Tzen CY, Wang SY, Yeh CN. Clinical diagnosis of gastrointestinal stromal tumor (GIST): from the molecular genetic point of view. Cancers (Basel). 2019, 11:10.3390\/cancers11050679","journal-title":"Cancers (Basel)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP0PPKOBNDT9LB","article-title":"DOG1 antibody is a highly sensitive and specific marker for gastrointestinal stromal tumors in cytology cell blocks","volume":"135","author":"Hwang DG","year":"2011","unstructured":"Hwang DG, Qian X, Hornick JL. DOG1 antibody is a highly sensitive and specific marker for gastrointestinal stromal tumors in cytology cell blocks. Am J Clin Pathol. 2011, 135:448-53. 10.1309\/AJCP0PPKOBNDT9LB","journal-title":"Am J Clin Pathol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199502000-00009","article-title":"Gastrointestinal stromal tumors - value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas","volume":"19","author":"Miettinen M","year":"1995","unstructured":"Miettinen M, Virolainen M, Maarit-Sarlomo-Rikala. Gastrointestinal stromal tumors - value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol. 1995, 19:207-16. 10.1097\/00000478-199502000-00009","journal-title":"Am J Surg Pathol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/his.12298","article-title":"Immunohistochemistry of soft tissue tumours - review with emphasis on 10 markers","volume":"64","author":"Miettinen M","year":"2014","unstructured":"Miettinen M. Immunohistochemistry of soft tissue tumours - review with emphasis on 10 markers. Histopathology. 2014, 64:101-18. 10.1111\/his.12298","journal-title":"Histopathology"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2013.01.001","article-title":"Gastrointestinal stromal tumors","volume":"42","author":"Miettinen M","year":"2013","unstructured":"Miettinen M, Lasota J. Gastrointestinal stromal tumors. Gastroenterol Clin North Am. 2013, 42:399-415. 10.1016\/j.gtc.2013.01.001","journal-title":"Gastroenterol Clin North Am"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i47.9133","article-title":"DOG1 is useful for diagnosis of KIT-negative gastrointestinal stromal tumor of stomach","volume":"19","author":"Wada T","year":"2013","unstructured":"Wada T, Tanabe S, Ishido K, et al.. DOG1 is useful for diagnosis of KIT-negative gastrointestinal stromal tumor of stomach. World J Gastroenterol. 2013, 19:9133-6. 10.3748\/wjg.v19.i47.9133","journal-title":"World J Gastroenterol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-015-0526-8","article-title":"The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines","volume":"19","author":"Nishida T","year":"2016","unstructured":"Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer. 2016, 19:3-14. 10.1007\/s10120-015-0526-8","journal-title":"Gastric Cancer"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.21037\/tgh.2018.04.01","article-title":"Differential diagnosis of gastrointestinal stromal tumor by histopathology and immunohistochemistry","volume":"3","author":"Hirota S","year":"2018","unstructured":"Hirota S. Differential diagnosis of gastrointestinal stromal tumor by histopathology and immunohistochemistry. Transl Gastroenterol Hepatol. 2018, 3:27. 10.21037\/tgh.2018.04.01","journal-title":"Transl Gastroenterol Hepatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1308\/003588412X13171221590935","article-title":"Gastric schwannoma: a benign tumour often mistaken clinically, radiologically and histopathologically for a gastrointestinal stromal tumour - a case series","volume":"94","author":"Williamson JM","year":"2012","unstructured":"Williamson JM, Wadley MS, Shepherd NA, Dwerryhouse S. Gastric schwannoma: a benign tumour often mistaken clinically, radiologically and histopathologically for a gastrointestinal stromal tumour - a case series. Ann R Coll Surg Engl. 2012, 94:245-9. 10.1308\/003588412X13171221590935","journal-title":"Ann R Coll Surg Engl"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071209","article-title":"Inflammatory fibroid polyp (Vanek\u2019s tumor): a retrospective multicentric analysis of 67 cases","volume":"17","author":"S\u00e1nchez MM","year":"2025","unstructured":"S\u00e1nchez MM, Dom\u00ednguez-Prieto V, Qian Zhang S, et al.. Inflammatory fibroid polyp (Vanek\u2019s tumor): a retrospective multicentric analysis of 67 cases. Cancers (Basel). 2025, 17:10.3390\/cancers17071209","journal-title":"Cancers (Basel)"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9440(10)63279-8","article-title":"The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status","volume":"165","author":"West RB","year":"2004","unstructured":"West RB, Corless CL, Chen X, et al.. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004, 165:107-13. 10.1016\/s0002-9440(10)63279-8","journal-title":"Am J Pathol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1789204","article-title":"Gene mutations in gastrointestinal stromal tumors: advances in treatment and mechanism research","volume":"11","author":"Cao L","year":"2024","unstructured":"Cao L, Tian W, Zhao Y, et al.. Gene mutations in gastrointestinal stromal tumors: advances in treatment and mechanism research. Glob Med Genet. 2024, 11:251-62. 10.1055\/s-0044-1789204","journal-title":"Glob Med Genet"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2016.09.15","article-title":"Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review","volume":"8","author":"Oppelt PJ","year":"2017","unstructured":"Oppelt PJ, Hirbe AC, Van Tine BA. Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review. J Gastrointest Oncol. 2017, 8:466-73. 10.21037\/jgo.2016.09.15","journal-title":"J Gastrointest Oncol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0305363101","article-title":"Targeted mutations of the juxtamembrane tyrosines in the KIT receptor tyrosine kinase selectively affect multiple cell lineages","volume":"101","author":"Kimura Y","year":"2004","unstructured":"Kimura Y, Jones N, Kl\u00fcppel M, et al.. Targeted mutations of the juxtamembrane tyrosines in the KIT receptor tyrosine kinase selectively affect multiple cell lineages. Proc Natl Acad Sci U S A. 2004, 101:6015-20. 10.1073\/pnas.0305363101","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2009.00983.x","article-title":"Imatinib treatment for gastrointestinal stromal tumour (GIST)","volume":"14","author":"Lopes LF","year":"2010","unstructured":"Lopes LF, Bacchi CE. Imatinib treatment for gastrointestinal stromal tumour (GIST). J Cell Mol Med. 2010, 14:42-50. 10.1111\/j.1582-4934.2009.00983.x","journal-title":"J Cell Mol Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/path.2798","article-title":"The GIST paradigm: lessons for other kinase-driven cancers","volume":"223","author":"Antonescu CR","year":"2011","unstructured":"Antonescu CR. The GIST paradigm: lessons for other kinase-driven cancers. J Pathol. 2011, 223:251-61. 10.1002\/path.2798","journal-title":"J Pathol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.694","article-title":"Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies","volume":"5","author":"Ou X","year":"2024","unstructured":"Ou X, Gao G, Habaz IA, Wang Y. Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies. MedComm (2020). 2024, 5:10.1002\/mco2.694","journal-title":"MedComm (2020)"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.265","article-title":"Understanding and targeting resistance mechanisms in cancer","volume":"4","author":"Lei ZN","year":"2023","unstructured":"Lei ZN, Tian Q, Teng QX, Wurpel JN, Zeng L, Pan Y, Chen ZS. Understanding and targeting resistance mechanisms in cancer. MedComm (2020). 2023, 4:10.1002\/mco2.265","journal-title":"MedComm (2020)"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.927587","article-title":"An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors","volume":"12","author":"Sun Y","year":"2022","unstructured":"Sun Y, Yue L, Xu P, Hu W. An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors. Front Oncol. 2022, 12:10.3389\/fonc.2022.927587","journal-title":"Front Oncol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goaf068","article-title":"An update on gastrointestinal stromal tumors (GISTs) with a focus on extragastrointestinal stromal tumors (EGISTs)","volume":"13","author":"Usama F","year":"2025","unstructured":"Usama F, Rasikh R, Hassam K, Rahman M, Khalil Ur Rehman F, Khan IW, Lau DT. An update on gastrointestinal stromal tumors (GISTs) with a focus on extragastrointestinal stromal tumors (EGISTs). Gastroenterol Rep (Oxf). 2025, 13:10.1093\/gastro\/goaf068","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_351231","article-title":"The GIST of advances in treatment of advanced gastrointestinal stromal tumor","volume":"42","author":"Schaefer I","year":"2022","unstructured":"Schaefer I, DeMatteo RP, Serrano C. The GIST of advances in treatment of advanced gastrointestinal stromal tumor. Am Soc Clin Oncol Educ Book. 2022, 42:885-9. 10.1200\/EDBK_351231","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17223635","article-title":"Seven shades of triple negativity: a review unveiling the low-grade spectrum of breast cancer","volume":"17","author":"Georgescu TA","year":"2025","unstructured":"Georgescu TA, Georgescu AC, Iacoban SR, Cre\u021boiu D, Copca N, Olinca MV. Seven shades of triple negativity: a review unveiling the low-grade spectrum of breast cancer. Cancers (Basel). 2025, 17:10.3390\/cancers17223635","journal-title":"Cancers (Basel)"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac242","article-title":"Efficacy and safety of avapritinib in treating unresectable or metastatic gastrointestinal stromal tumors: a phase I\/II, open-label, multicenter study","volume":"28","author":"Li J","year":"2023","unstructured":"Li J, Zhang X, Deng Y, et al.. Efficacy and safety of avapritinib in treating unresectable or metastatic gastrointestinal stromal tumors: a phase I\/II, open-label, multicenter study. Oncologist. 2023, 28:10.1093\/oncolo\/oyac242","journal-title":"Oncologist"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2012.599","article-title":"A novel PDGFRA mutation in gastrointestinal stromal tumours, L839P, is sensitive to imatinib in vitro","volume":"3","author":"Bai C","year":"2012","unstructured":"Bai C, Liu X, Zheng JM, et al.. A novel PDGFRA mutation in gastrointestinal stromal tumours, L839P, is sensitive to imatinib in vitro. Oncol Lett. 2012, 3:1139-43. 10.3892\/ol.2012.599","journal-title":"Oncol Lett"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i8.2303","article-title":"Succinate dehydrogenase-deficient gastrointestinal stromal tumors","volume":"21","author":"Wang YM","year":"2015","unstructured":"Wang YM, Gu ML, Ji F. Succinate dehydrogenase-deficient gastrointestinal stromal tumors. World J Gastroenterol. 2015, 21:2303-14. 10.3748\/wjg.v21.i8.2303","journal-title":"World J Gastroenterol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00117","article-title":"Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors","volume":"3","author":"Belinsky MG","year":"2013","unstructured":"Belinsky MG, Rink L, von Mehren M. Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors. Front Oncol. 2013, 3:117. 10.3389\/fonc.2013.00117","journal-title":"Front Oncol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-6-52","article-title":"Multifocal gastric gastrointestinal stromal tumors (GISTs) with lymph node metastases in children and young adults: a comparative clinical and histomorphological study of three cases including a new case of Carney triad","volume":"6","author":"Otto C","year":"2011","unstructured":"Otto C, Agaimy A, Braun A, et al.. Multifocal gastric gastrointestinal stromal tumors (GISTs) with lymph node metastases in children and young adults: a comparative clinical and histomorphological study of three cases including a new case of Carney triad. Diagn Pathol. 2011, 6:52. 10.1186\/1746-1596-6-52","journal-title":"Diagn Pathol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3182260752","article-title":"Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age","volume":"35","author":"Miettinen M","year":"2011","unstructured":"Miettinen M, Wang ZF, Sarlomo-Rikala M, Osuch C, Rutkowski P, Lasota J. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol. 2011, 35:1712-21. 10.1097\/PAS.0b013e3182260752","journal-title":"Am J Surg Pathol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104477","article-title":"Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC","volume":"10","author":"Cuvelier C","year":"2025","unstructured":"Cuvelier C, Brahmi M, Sobhani I, et al.. Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC. ESMO Open. 2025, 10:10.1016\/j.esmoop.2025.104477","journal-title":"ESMO Open"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3181bf15e3","article-title":"Clinical and genetic aspects of neurofibromatosis 1","volume":"12","author":"Jett K","year":"2010","unstructured":"Jett K, Friedman JM. Clinical and genetic aspects of neurofibromatosis 1. Genet Med. 2010, 12:1-11. 10.1097\/GIM.0b013e3181bf15e3","journal-title":"Genet Med"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1007\/s44162-024-00030-5","article-title":"Neurofibromatosis type 1 with three synchronous tumors","volume":"3","author":"Kakkat S","year":"2024","unstructured":"Kakkat S, Zacharia GS, Ravindran R, Poovan C, Jacob A. Neurofibromatosis type 1 with three synchronous tumors. J Rare Dis. 2024, 3:6. 10.1007\/s44162-024-00030-5","journal-title":"J Rare Dis"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v11.i10.2336","article-title":"Neurofibromatosis type 1 with multiple gastrointestinal stromal tumors: a case report","volume":"11","author":"Yao MQ","year":"2023","unstructured":"Yao MQ, Jiang YP, Yi BH, Yang Y, Sun DZ, Fan JX. Neurofibromatosis type 1 with multiple gastrointestinal stromal tumors: a case report. World J Clin Cases. 2023, 11:2336-42. 10.12998\/wjcc.v11.i10.2336","journal-title":"World J Clin Cases"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-008-0514-z","article-title":"Neurofibromatosis type 1-related gastrointestinal stromal tumors: a special reference to loss of heterozygosity at 14q and 22q","volume":"135","author":"Yamamoto H","year":"2009","unstructured":"Yamamoto H, Tobo T, Nakamori M, et al.. Neurofibromatosis type 1-related gastrointestinal stromal tumors: a special reference to loss of heterozygosity at 14q and 22q. J Cancer Res Clin Oncol. 2009, 135:791-8. 10.1007\/s00432-008-0514-z","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-23-767","article-title":"Treatment of BRAF V600E mutant gastrointestinal stromal tumor with dabrafenib: a case report","volume":"15","author":"Gowda S","year":"2024","unstructured":"Gowda S, Sandow L, Heinrich MC. Treatment of BRAF V600E mutant gastrointestinal stromal tumor with dabrafenib: a case report. J Gastrointest Oncol. 2024, 15:788-93. 10.21037\/jgo-23-767","journal-title":"J Gastrointest Oncol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco E","year":"2018","unstructured":"Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018, 15:731-47. 10.1038\/s41571-018-0113-0","journal-title":"Nat Rev Clin Oncol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0256","article-title":"Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic","volume":"2","author":"Boikos SA","year":"2016","unstructured":"Boikos SA, Pappo AS, Killian JK, et al.. Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol. 2016, 2:922-8. 10.1001\/jamaoncol.2016.0256","journal-title":"JAMA Oncol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215330","article-title":"Current molecular profile of gastrointestinal stromal tumors and systemic therapeutic implications","volume":"14","author":"Mathias-Machado MC","year":"2022","unstructured":"Mathias-Machado MC, de Jesus VH, de Carvalho Oliveira LJ, Neumann M, Peixoto RD. Current molecular profile of gastrointestinal stromal tumors and systemic therapeutic implications. Cancers (Basel). 2022, 14:10.3390\/cancers14215330","journal-title":"Cancers (Basel)"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00606-4","article-title":"New treatment strategies for advanced-stage gastrointestinal stromal tumours","volume":"19","author":"Klug LR","year":"2022","unstructured":"Klug LR, Khosroyani HM, Kent JD, Heinrich MC. New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nat Rev Clin Oncol. 2022, 19:328-41. 10.1038\/s41571-022-00606-4","journal-title":"Nat Rev Clin Oncol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2010.25.11.1543","article-title":"Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea","volume":"25","author":"Kang YK","year":"2010","unstructured":"Kang YK, Kim KM, Sohn T, et al.. Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. J Korean Med Sci. 2010, 25:1543-52. 10.3346\/jkms.2010.25.11.1543","journal-title":"J Korean Med Sci"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051498","article-title":"Molecular mechanisms of gastrointestinal stromal tumors and their impact on systemic therapy decision","volume":"15","author":"Unk M","year":"2023","unstructured":"Unk M, Jezer\u0161ek Novakovi\u0107 B, Novakovi\u0107 S. Molecular mechanisms of gastrointestinal stromal tumors and their impact on systemic therapy decision. Cancers (Basel). 2023, 15:10.3390\/cancers15051498","journal-title":"Cancers (Basel)"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.25122\/jml-2021-0110","article-title":"GIST: correlation of risk classifications and outcome","volume":"15","author":"Kersting S","year":"2022","unstructured":"Kersting S, Janot-Matuschek MS, Schnitzler C, Chourio Barboza DE, Uhl W, Mittelk\u00f6tter U. GIST: correlation of risk classifications and outcome. J Med Life. 2022, 15:932-43. 10.25122\/jml-2021-0110","journal-title":"J Med Life"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1007\/s101200050013","article-title":"Peritoneal and serum tumor markers predict recurrence and survival of patients with resectable gastric cancer","volume":"2","author":"Bold RJ","year":"1999","unstructured":"Bold RJ, Ota DM, Ajani JA, Mansfield PF. Peritoneal and serum tumor markers predict recurrence and survival of patients with resectable gastric cancer. Gastric Cancer. 1999, 2:1-7. 10.1007\/s101200050013","journal-title":"Gastric Cancer"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm243","article-title":"Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features","volume":"18","author":"Badalamenti G","year":"2007","unstructured":"Badalamenti G, Rodolico V, Fulfaro F, et al.. Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features. Ann Oncol. 2007, 18:136-40. 10.1093\/annonc\/mdm243","journal-title":"Ann Oncol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604217","article-title":"Clinical implications of mutational analysis in gastrointestinal stromal tumours","volume":"98","author":"Hoeben A","year":"2008","unstructured":"Hoeben A, Sch\u00f6ffski P, Debiec-Rychter M. Clinical implications of mutational analysis in gastrointestinal stromal tumours. Br J Cancer. 2008, 98:684-8. 10.1038\/sj.bjc.6604217","journal-title":"Br J Cancer"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.1891","article-title":"KIT exon 11 codon 557\/558 deletion\/insertion mutations define a subset of gastrointestinal stromal tumors with malignant potential","volume":"14","author":"Kontogianni-Katsarou K","year":"2008","unstructured":"Kontogianni-Katsarou K, Dimitriadis E, Lariou C, Kairi-Vassilatou E, Pandis N, Kondi-Paphiti A. KIT exon 11 codon 557\/558 deletion\/insertion mutations define a subset of gastrointestinal stromal tumors with malignant potential. World J Gastroenterol. 2008, 14:1891-7. 10.3748\/wjg.14.1891","journal-title":"World J Gastroenterol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-013-0018-7","article-title":"Extended adjuvant therapy with imatinib in patients with gastrointestinal stromal tumors: recommendations for patient selection, risk assessment, and molecular response monitoring","volume":"17","author":"Rutkowski P","year":"2013","unstructured":"Rutkowski P, Przyby\u0142 J, Zdzienicki M. Extended adjuvant therapy with imatinib in patients with gastrointestinal stromal tumors: recommendations for patient selection, risk assessment, and molecular response monitoring. Mol Diagn Ther. 2013, 17:9-19. 10.1007\/s40291-013-0018-7","journal-title":"Mol Diagn Ther"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0487","article-title":"Resistance to avapritinib in PDGFRA-driven gist is caused by secondary mutations in the PDGFRA kinase domain","volume":"11","author":"Grunewald S","year":"2021","unstructured":"Grunewald S, Klug LR, M\u00fchlenberg T, et al.. Resistance to avapritinib in PDGFRA-driven gist is caused by secondary mutations in the PDGFRA kinase domain. Cancer Discov. 2021, 11:108-25. 10.1158\/2159-8290.CD-20-0487","journal-title":"Cancer Discov"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153879","article-title":"KIT and PDGFRA variants and the survival of patients with gastrointestinal stromal tumor treated with adjuvant imatinib","volume":"15","author":"Joensuu H","year":"2023","unstructured":"Joensuu H. KIT and PDGFRA variants and the survival of patients with gastrointestinal stromal tumor treated with adjuvant imatinib. Cancers (Basel). 2023, 15:10.3390\/cancers15153879","journal-title":"Cancers (Basel)"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer biomarkers: emerging trends and clinical implications for personalized treatment","volume":"187","author":"Passaro A","year":"2024","unstructured":"Passaro A, Al Bakir M, Hamilton EG, et al.. Cancer biomarkers: emerging trends and clinical implications for personalized treatment. Cell. 2024, 187:1617-35. 10.1016\/j.cell.2024.02.041","journal-title":"Cell"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1172\/JCI124108","article-title":"Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor","volume":"129","author":"Vitiello GA","year":"2019","unstructured":"Vitiello GA, Bowler TG, Liu M, et al.. Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor. J Clin Invest. 2019, 129:1863-77. 10.1172\/JCI124108","journal-title":"J Clin Invest"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0092","article-title":"Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor","volume":"3","author":"Killian JK","year":"2013","unstructured":"Killian JK, Kim SY, Miettinen M, et al.. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 2013, 3:648-57. 10.1158\/2159-8290.CD-13-0092","journal-title":"Cancer Discov"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-1606","article-title":"Epigenetic alterations and mechanisms that drive resistance to targeted cancer therapies","volume":"81","author":"Wajapeyee N","year":"2021","unstructured":"Wajapeyee N, Gupta R. Epigenetic alterations and mechanisms that drive resistance to targeted cancer therapies. Cancer Res. 2021, 81:5589-95. 10.1158\/0008-5472.CAN-21-1606","journal-title":"Cancer Res"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.763790","article-title":"Circulating tumor DNA and minimal residual disease (MRD) in solid tumors: current horizons and future perspectives","volume":"11","author":"Peng Y","year":"2021","unstructured":"Peng Y, Mei W, Ma K, Zeng C. Circulating tumor DNA and minimal residual disease (MRD) in solid tumors: current horizons and future perspectives. Front Oncol. 2021, 11:10.3389\/fonc.2021.763790","journal-title":"Front Oncol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70931","article-title":"The mechanisms of imatinib resistance in gastrointestinal stromal tumours: theoretical basis and therapeutic aspect","volume":"29","author":"Abudurexiti N","year":"2025","unstructured":"Abudurexiti N, Lou Y, Wu M, Huang Y, Huang S, Guo K, Zheng S. The mechanisms of imatinib resistance in gastrointestinal stromal tumours: theoretical basis and therapeutic aspect. J Cell Mol Med. 2025, 29:10.1111\/jcmm.70931","journal-title":"J Cell Mol Med"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1177\/11795549251346653","article-title":"Primary management of localized gastrointestinal stromal tumors with imatinib monotherapy: an alternative to resection of patients precluded from surgery","volume":"19","author":"Wang JS","year":"2025","unstructured":"Wang JS, Ellsworth BL, Al-Marayaty R, et al.. Primary management of localized gastrointestinal stromal tumors with imatinib monotherapy: an alternative to resection of patients precluded from surgery. Clin Med Insights Oncol. 2025, 19:10.1177\/11795549251346653","journal-title":"Clin Med Insights Oncol"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.5751","article-title":"Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an exploratory analysis of a randomized clinical trial","volume":"3","author":"Joensuu H","year":"2017","unstructured":"Joensuu H, Wardelmann E, Sihto H, et al.. Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an exploratory analysis of a randomized clinical trial. JAMA Oncol. 2017, 3:602-9. 10.1001\/jamaoncol.2016.5751","journal-title":"JAMA Oncol"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani M","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, et al.. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013, 122:872-84. 10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.3747\/co.v17i4.560","article-title":"Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence","volume":"17","author":"Younus J","year":"2010","unstructured":"Younus J, Verma S, Franek J, Coakley N. Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence. Curr Oncol. 2010, 17:4-10. 10.3747\/co.v17i4.560","journal-title":"Curr Oncol"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3120","article-title":"CCR 20th anniversary commentary: a genetic mechanism of imatinib resistance in gastrointestinal stromal tumor-where are we a decade later?","volume":"21","author":"Antonescu CR","year":"2015","unstructured":"Antonescu CR, DeMatteo RP. CCR 20th anniversary commentary: a genetic mechanism of imatinib resistance in gastrointestinal stromal tumor-where are we a decade later?. Clin Cancer Res. 2015, 21:3363-5. 10.1158\/1078-0432.CCR-14-3120","journal-title":"Clin Cancer Res"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0812413106","article-title":"KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients","volume":"106","author":"Gajiwala KS","year":"2009","unstructured":"Gajiwala KS, Wu JC, Christensen J, et al.. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA. 2009, 106:1542-7. 10.1073\/pnas.0812413106","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.158","article-title":"Drug rechallenge and treatment beyond progression - implications for drug resistance","volume":"10","author":"Kuczynski EA","year":"2013","unstructured":"Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression - implications for drug resistance. Nat Rev Clin Oncol. 2013, 10:571-87. 10.1038\/nrclinonc.2013.158","journal-title":"Nat Rev Clin Oncol"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.9394","article-title":"Efficacy and safety of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial","volume":"30","author":"George S","year":"2012","unstructured":"George S, Wang Q, Heinrich MC, et al.. Efficacy and safety of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012, 30:2401-7. 10.1200\/JCO.2011.39.9394","journal-title":"J Clin Oncol"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw228","article-title":"Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy","volume":"27","author":"Ben-Ami E","year":"2016","unstructured":"Ben-Ami E, Barysauskas CM, von Mehren M, et al.. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016, 27:1794-9. 10.1093\/annonc\/mdw228","journal-title":"Ann Oncol"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03918-x","article-title":"Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial","volume":"31","author":"Marchetti P","year":"2025","unstructured":"Marchetti P, Curigliano G, Biffoni M, et al.. Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial. Nat Med. 2025, 31:3514-23. 10.1038\/s41591-025-03918-x","journal-title":"Nat Med"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1446945","article-title":"Efficacy and safety of regorafenib for the treatment of metastatic colorectal cancer in routine clinical practice: results from a Spanish hospital","volume":"14","author":"Sotoca Rubio P","year":"2024","unstructured":"Sotoca Rubio P, Barrill Corpa AM, Alia Navarro V, et al.. Efficacy and safety of regorafenib for the treatment of metastatic colorectal cancer in routine clinical practice: results from a Spanish hospital. Front Oncol. 2024, 14:10.3389\/fonc.2024.1446945","journal-title":"Front Oncol"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich MC","year":"2020","unstructured":"Heinrich MC, Jones RL, von Mehren M, et al.. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020, 21:935-46. 10.1016\/S1470-2045(20)30269-2","journal-title":"Lancet Oncol"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1858","article-title":"Robust activity of avapritinib, potent and highly selective inhibitor of mutated kit, in patient-derived xenograft models of gastrointestinal stromal tumors","volume":"25","author":"Gebreyohannes YK","year":"2019","unstructured":"Gebreyohannes YK, Wozniak A, Zhai ME, et al.. Robust activity of avapritinib, potent and highly selective inhibitor of mutated kit, in patient-derived xenograft models of gastrointestinal stromal tumors. Clin Cancer Res. 2019, 25:609-18. 10.1158\/1078-0432.CCR-18-1858","journal-title":"Clin Cancer Res"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2025.04.006","article-title":"Gastrointestinal stromal tumor: current approaches and future directions in the treatment of advanced disease","volume":"39","author":"Cicala CM","year":"2025","unstructured":"Cicala CM, Bauer S, Heinrich MC, Serrano C. Gastrointestinal stromal tumor: current approaches and future directions in the treatment of advanced disease. Hematol Oncol Clin North Am. 2025, 39:773-84. 10.1016\/j.hoc.2025.04.006","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007539","article-title":"Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis","volume":"6","author":"Reiter A","year":"2022","unstructured":"Reiter A, Schwaab J, DeAngelo DJ, et al.. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. Blood Adv. 2022, 6:5750-62. 10.1182\/bloodadvances.2022007539","journal-title":"Blood Adv"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00522","article-title":"Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: a phase I study of ripretinib","volume":"38","author":"Janku F","year":"2020","unstructured":"Janku F, Abdul Razak AR, Chi P, et al.. Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: a phase I study of ripretinib. J Clin Oncol. 2020, 38:3294-303. 10.1200\/JCO.20.00522","journal-title":"J Clin Oncol"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.04.006","article-title":"Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants","volume":"35","author":"Smith BD","year":"2019","unstructured":"Smith BD, Kaufman MD, Lu WP, et al.. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell. 2019, 35:738-51. 10.1016\/j.ccell.2019.04.006","journal-title":"Cancer Cell"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2400","article-title":"FDA approval summary: ripretinib for advanced gastrointestinal stromal tumor","volume":"29","author":"Kumar V","year":"2023","unstructured":"Kumar V, Doros L, Thompson M, et al.. FDA approval summary: ripretinib for advanced gastrointestinal stromal tumor. Clin Cancer Res. 2023, 29:2020-4. 10.1158\/1078-0432.CCR-22-2400","journal-title":"Clin Cancer Res"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473224","article-title":"Navigating ongoing challenges in GI stromal tumors","volume":"45","author":"Joensuu H","year":"2025","unstructured":"Joensuu H, Miyashita H, George S, Sicklick J. Navigating ongoing challenges in GI stromal tumors. Am Soc Clin Oncol Educ Book. 2025, 45:10.1200\/EDBK-25-473224","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.86","article-title":"Succinate dehydrogenase deficiency is associated with decreased 5-hydroxymethylcytosine production in gastrointestinal stromal tumors: implications for mechanisms of tumorigenesis","volume":"26","author":"Mason EF","year":"2013","unstructured":"Mason EF, Hornick JL. Succinate dehydrogenase deficiency is associated with decreased 5-hydroxymethylcytosine production in gastrointestinal stromal tumors: implications for mechanisms of tumorigenesis. Mod Pathol. 2013, 26:1492-7. 10.1038\/modpathol.2013.86","journal-title":"Mod Pathol"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211023278","article-title":"Targeted therapy in SDH-deficient GIST","volume":"13","author":"Nannini M","year":"2021","unstructured":"Nannini M, Rizzo A, Indio V, Schipani A, Astolfi A, Pantaleo MA. Targeted therapy in SDH-deficient GIST. Ther Adv Med Oncol. 2021, 13:10.1177\/17588359211023278","journal-title":"Ther Adv Med Oncol"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.70023","article-title":"Epi-immunotherapy in cancer treatment: mechanisms, clinical progress, and future directions","volume":"4","author":"Lu N","year":"2025","unstructured":"Lu N, Rong G, Han W. Epi-immunotherapy in cancer treatment: mechanisms, clinical progress, and future directions. Cancer Innov. 2025, 4:10.1002\/cai2.70023","journal-title":"Cancer Innov"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad167","article-title":"Molecular advances in the treatment of advanced gastrointestinal stromal tumor","volume":"28","author":"Venkataraman V","year":"2023","unstructured":"Venkataraman V, George S, Cote GM. Molecular advances in the treatment of advanced gastrointestinal stromal tumor. Oncologist. 2023, 28:671-81. 10.1093\/oncolo\/oyad167","journal-title":"Oncologist"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015478","article-title":"Relationship between efficacy of sunitinib and KIT mutation of patients with advanced gastrointestinal stromal tumors after failure of imatinib: a systematic review","volume":"98","author":"Xie F","year":"2019","unstructured":"Xie F, Xiao W, Jiang Y, Xia X, Wang Y. Relationship between efficacy of sunitinib and KIT mutation of patients with advanced gastrointestinal stromal tumors after failure of imatinib: a systematic review. Medicine (Baltimore). 2019, 98:10.1097\/MD.0000000000015478","journal-title":"Medicine (Baltimore)"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.101993","article-title":"Evolving role of regorafenib for the treatment of advanced cancers","volume":"86","author":"Grothey A","year":"2020","unstructured":"Grothey A, Blay JY, Pavlakis N, Yoshino T, Bruix J. Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treat Rev. 2020, 86:10.1016\/j.ctrv.2020.101993","journal-title":"Cancer Treat Rev"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2020-0178","article-title":"Avapritinib in advanced gastrointestinal stromal tumor: case series and review of\u00a0the\u00a0literature from a tertiary care center in India","volume":"7","author":"Verma S","year":"2021","unstructured":"Verma S, Reddy R, Chandrashekhara SH, Shamim SA, Tripathy S, Rastogi S. Avapritinib in advanced gastrointestinal stromal tumor: case series and review of\u00a0the\u00a0literature from a tertiary care center in India. Future Sci OA. 2021, 7:10.2144\/fsoa-2020-0178","journal-title":"Future Sci OA"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld AJ","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020, 37:443-55. 10.1016\/j.ccell.2020.03.017","journal-title":"Cancer Cell"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115795","article-title":"Molecular mechanisms of tumor progression and new therapeutic strategies for urological cancers","volume":"24","author":"Ruiz de Porras V","year":"2023","unstructured":"Ruiz de Porras V, Font A. Molecular mechanisms of tumor progression and new therapeutic strategies for urological cancers. Int J Mol Sci. 2023, 24:10.3390\/ijms242115795","journal-title":"Int J Mol Sci"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.9b00274","article-title":"Avapritinib: a selective inhibitor of KIT and PDGRA\u03b1 that reverses ABCB1 and ABCG2-mediated multidrug resistance in cancer cell lines","volume":"16","author":"Wu CP","year":"2019","unstructured":"Wu CP, Lusvarghi S, Wang JC, Hsiao SH, Huang YH, Hung TH, Ambudkar SV. Avapritinib: a selective inhibitor of KIT and PDGRA\u03b1 that reverses ABCB1 and ABCG2-mediated multidrug resistance in cancer cell lines. Mol Pharm. 2019, 16:3040-52. 10.1021\/acs.molpharmaceut.9b00274","journal-title":"Mol Pharm"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.933248","article-title":"Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors","volume":"12","author":"Hu X","year":"2022","unstructured":"Hu X, Wang Z, Su P, Zhang Q, Kou Y. Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors. Front Oncol. 2022, 12:10.3389\/fonc.2022.933248","journal-title":"Front Oncol"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01197","article-title":"KIT ATP-binding pocket\/activation loop mutations in GI stromal tumor: emerging mechanisms of kinase inhibitor escape","volume":"42","author":"M\u00fchlenberg T","year":"2024","unstructured":"M\u00fchlenberg T, Falkenhorst J, Schulz T, et al.. KIT ATP-binding pocket\/activation loop mutations in GI stromal tumor: emerging mechanisms of kinase inhibitor escape. J Clin Oncol. 2024, 42:1439-49. 10.1200\/JCO.23.01197","journal-title":"J Clin Oncol"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06486-3","article-title":"Advances in tumor subclone formation and mechanisms of growth and invasion","volume":"23","author":"Zhang Y","year":"2025","unstructured":"Zhang Y, Wang W. Advances in tumor subclone formation and mechanisms of growth and invasion. J Transl Med. 2025, 23:461. 10.1186\/s12967-025-06486-3","journal-title":"J Transl Med"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.06.005","article-title":"Tumour heterogeneity and the evolution of polyclonal drug resistance","volume":"8","author":"Burrell RA","year":"2014","unstructured":"Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol. 2014, 8:1095-111. 10.1016\/j.molonc.2014.06.005","journal-title":"Mol Oncol"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2024.189","article-title":"Acquired resistance to molecularly targeted therapies for cancer","volume":"8","author":"Stubbs NM","year":"2025","unstructured":"Stubbs NM, Roady TJ, Schwermann MP, et al.. Acquired resistance to molecularly targeted therapies for cancer. Cancer Drug Resist. 2025, 8:27. 10.20517\/cdr.2024.189","journal-title":"Cancer Drug Resist"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.248","article-title":"Clonal evolution in hematological malignancies and therapeutic implications","volume":"28","author":"Landau DA","year":"2014","unstructured":"Landau DA, Carter SL, Getz G, Wu CJ. Clonal evolution in hematological malignancies and therapeutic implications. Leukemia. 2014, 28:34-43. 10.1038\/leu.2013.248","journal-title":"Leukemia"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01794-0","article-title":"Ripretinib: a review in gastrointestinal stromal tumours as fourth-or later-line of therapy","volume":"82","author":"Fung S","year":"2022","unstructured":"Fung S, Shirley M. Ripretinib: a review in gastrointestinal stromal tumours as fourth-or later-line of therapy. Drugs. 2022, 82:1541-8. 10.1007\/s40265-022-01794-0","journal-title":"Drugs"},{"key":"ref122","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.5496","article-title":"Combined inhibition of heat shock proteins 90 and 70 leads to simultaneous degradation of the oncogenic signaling proteins involved in muscle invasive bladder cancer","volume":"6","author":"Cavanaugh A","year":"2015","unstructured":"Cavanaugh A, Juengst B, Sheridan K, Danella JF, Williams H. Combined inhibition of heat shock proteins 90 and 70 leads to simultaneous degradation of the oncogenic signaling proteins involved in muscle invasive bladder cancer. Oncotarget. 2015, 6:39821-38.","journal-title":"Oncotarget"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.3390\/ph18081083","article-title":"Combination strategies with HSP90 inhibitors in cancer therapy: mechanisms, challenges, and future perspectives","volume":"18","author":"Kim Y","year":"2025","unstructured":"Kim Y, Lim SY, Kim HO, et al.. Combination strategies with HSP90 inhibitors in cancer therapy: mechanisms, challenges, and future perspectives. Pharmaceuticals (Basel). 2025, 18:10.3390\/ph18081083","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang Q","year":"2022","unstructured":"Tang Q, Chen Y, Li X, et al.. The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022, 13:10.3389\/fimmu.2022.964442","journal-title":"Front Immunol"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202509880","article-title":"Advances and strategies in enhancing mRNA cancer vaccines","volume":"37","author":"Zhang M","year":"2025","unstructured":"Zhang M, Chen S, Hu H, Ong Y, Ni Q. Advances and strategies in enhancing mRNA cancer vaccines. Adv Mater. 2025, 37:10.1002\/adma.202509880","journal-title":"Adv Mater"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-025-00373-5","article-title":"Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications","volume":"6","author":"Ma C","year":"2025","unstructured":"Ma C, Cheng J, Gu J, Wang Q. Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications. Mol Biomed. 2025, 6:132. 10.1186\/s43556-025-00373-5","journal-title":"Mol Biomed"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.21037\/atm-25-34","article-title":"Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment","volume":"13","author":"Jamalinia M","year":"2025","unstructured":"Jamalinia M, Weiskirchen R. Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment. Ann Transl Med. 2025, 13:18. 10.21037\/atm-25-34","journal-title":"Ann Transl Med"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.005","article-title":"Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Casali PG","year":"2022","unstructured":"Casali PG, Blay JY, Abecassis N, et al.. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:20-33. 10.1016\/j.annonc.2021.09.005","journal-title":"Ann Oncol"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00421-9","article-title":"Deep learning predicts patients outcome and mutations from digitized histology slides in gastrointestinal stromal tumor","volume":"7","author":"Fu Y","year":"2023","unstructured":"Fu Y, Karanian M, Perret R, et al.. Deep learning predicts patients outcome and mutations from digitized histology slides in gastrointestinal stromal tumor. NPJ Precis Oncol. 2023, 7:71. 10.1038\/s41698-023-00421-9","journal-title":"NPJ Precis Oncol"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-605808","article-title":"Secondary mutations as mediators of resistance to targeted therapy in leukemia","volume":"125","author":"Daver N","year":"2015","unstructured":"Daver N, Cortes J, Ravandi F, Patel KP, Burger JA, Konopleva M, Kantarjian H. Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood. 2015, 125:3236-45. 10.1182\/blood-2014-10-605808","journal-title":"Blood"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13081983","article-title":"The convergent frontier: integrating molecular, computational, and surgical sciences in oncology","volume":"13","author":"Alshammari AH","year":"2025","unstructured":"Alshammari AH, Hirotsu T, Hatakeyama H, di Luccio E. The convergent frontier: integrating molecular, computational, and surgical sciences in oncology. Biomedicines. 2025, 13:10.3390\/biomedicines13081983","journal-title":"Biomedicines"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/449100-gastrointestinal-stromal-tumors-histopathological-spectrum-molecular-subtypes-and-implications-for-targeted-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:37:30Z","timestamp":1767983850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/449100-gastrointestinal-stromal-tumors-histopathological-spectrum-molecular-subtypes-and-implications-for-targeted-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":131,"URL":"https:\/\/doi.org\/10.7759\/cureus.101180","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,9]]}}}